2002;1:111 -8. Aucouturier J, Dupius L, Deville S, et al. Adjuvants designed for veterinary and human vaccines. Vaccine 2001;19:2666-72. Babiak A, Steinhauser M, Götz M, et al. Frequent T cell responses against immunogenic targets in lung cancer patients for targeted immunotherapy Oncol Rep. 2014;31:384-90. Barnhill DR, Hoskins WJ, Heller PB, et al., The second-look surgical reassessment for epithelial ovarian carcinoma. Gynecol Oncol . 1984;19:148-54. Bejrananda T, Phukaoluon M, Boonpipattanapong T, et al. WT1 expression as an independent marker of poor prognosis in colorectal cancers. Cancer Biomark. 2010 - 2011;8:35-42. Bendell JC, Kim TW, Goh BC, et al. Clinical activity and safety of cobimetinib (cobi) and atezolizumab in colorectal cancer (CRC). J Clin Oncol. 2016;34(suppl): Abstr. # 3502. Bianchini G, Balko JM, Mayer IA, et al. Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. Nat Rev Clin Oncol. 2016;13:674 –90. Bleakley M, Riddell SR. Exploiting T cells specific for human minor histocomp atibility antigens for therapy of leukemia. Immunol Cell Biol. 2011;89:396 -407. Boddu P, Kantarjian H, Garcia-Manero G, et al. The emerging role of immune checkpoint based approaches in AML and MDS. Leuk Lymphoma. 2018;59:790-802. d Boland PM, Ma WW. Immunotherapy for colorectal cancer. Cancers. 2017;9:50. Bose P, Vacchani P, Cortes JE, et al. Treatment of Relapsed/Refractory Acute Myeloid Leukemia. Curr Treat Options Oncol.